Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Therasphere for Unresectable Primary or Secondary Liver Neoplasia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02960620
Expanded Access Status : Available
First Posted : November 9, 2016
Last Update Posted : February 3, 2021
Sponsor:
Collaborators:
Biocompatibles UK Ltd
BTG International Inc.
Information provided by (Responsible Party):
H. Lee Moffitt Cancer Center and Research Institute

Tracking Information
First Submitted Date November 8, 2016
First Posted Date November 9, 2016
Last Update Posted Date February 3, 2021
 
Descriptive Information
Brief Title Therasphere for Unresectable Primary or Secondary Liver Neoplasia
Brief Summary This is not a research study. The purpose is to provide supervised access to TheraSphere® therapy at this institution.
Detailed Description Not Provided
Study Type Expanded Access
Intervention Device: TheraSphere Treatment
TheraSphere® is delivered into the liver tumor through a catheter placed into the hepatic artery. The hepatic artery provides the main blood supply to the tumor in the liver, whereas the portal vein supplies blood to normal liver parenchyma. TheraSphere® is embolized within the tumor and exerts a local beta radiation radiotherapeutic effect with relatively limited concurrent injury to surrounding normal tissue.
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Expanded Access Status Available
Contacts
Contact: Junsung Choi, M.D. 813-745-4615 junsung.choi@moffitt.org
Listed Location Countries United States
Removed Location Countries  
 
Administrative Information
NCT Number NCT02960620
Responsible Party H. Lee Moffitt Cancer Center and Research Institute
Study Sponsor H. Lee Moffitt Cancer Center and Research Institute
Collaborators
  • Biocompatibles UK Ltd
  • BTG International Inc.
Investigators
Principal Investigator: Junsung Choi, M.D. H. Lee Moffitt Cancer Center and Research Institute
PRS Account H. Lee Moffitt Cancer Center and Research Institute
Verification Date February 2021